LYNPARZA (olaparib)

LynparzaTM (olaparib) is a first‐in‐class PARP inhibitor (PARPi) that allows women with BRCA mutated (BRCAm) platinum‐sensitive relapsed high-grade serous ovarian cancer to extend progression‐free survival (PFS).1-3

Prescribing Information

Dosing and Administration

Lynparza is the only approved oral maintenance therapy for BRCAm platinum-sensitive relapsed high-grade serous ovarian cancer patients.4 

The recommended dose of Lynparza is 400 mg (eight 50 mg capsules) taken twice daily, equivalent to a total daily dose of 800 mg.4

Image showing how to take Lynparza 400mg around morning and evening mealtimes
Image showing how to take Lynparza 400mg around morning and evening mealtimes